Literature DB >> 26003884

Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection.

Xiquan Liang1, Jason Potter2, Shantanu Kumar1, Yanfei Zou1, Rene Quintanilla1, Mahalakshmi Sridharan1, Jason Carte1, Wen Chen1, Natasha Roark1, Sridhar Ranganathan1, Namritha Ravinder1, Jonathan D Chesnut1.   

Abstract

CRISPR-Cas9 systems provide a platform for high efficiency genome editing that are enabling innovative applications of mammalian cell engineering. However, the delivery of Cas9 and synthesis of guide RNA (gRNA) remain as steps that can limit overall efficiency and ease of use. Here we describe methods for rapid synthesis of gRNA and for delivery of Cas9 protein/gRNA ribonucleoprotein complexes (Cas9 RNPs) into a variety of mammalian cells through liposome-mediated transfection or electroporation. Using these methods, we report nuclease-mediated indel rates of up to 94% in Jurkat T cells and 87% in induced pluripotent stem cells (iPSC) for a single target. When we used this approach for multigene targeting in Jurkat cells we found that two-locus and three-locus indels were achieved in approximately 93% and 65% of the resulting isolated cell lines, respectively. Further, we found that the off-target cleavage rate is reduced using Cas9 protein when compared to plasmid DNA transfection. Taken together, we present a streamlined cell engineering workflow that enables gRNA design to analysis of edited cells in as little as four days and results in highly efficient genome modulation in hard-to-transfect cells. The reagent preparation and delivery to cells is amenable to high throughput, multiplexed genome-wide cell engineering.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CRISPR; Cas9; Gene editing; Multiplex; Transfection; gRNA

Mesh:

Substances:

Year:  2015        PMID: 26003884     DOI: 10.1016/j.jbiotec.2015.04.024

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  241 in total

1.  Autophagy-dependent cancer cells circumvent loss of the upstream regulator RB1CC1/FIP200 and loss of LC3 conjugation by similar mechanisms.

Authors:  Christina G Towers; Darya Wodetzki; Andrew Thorburn
Journal:  Autophagy       Date:  2020-03-18       Impact factor: 16.016

Review 2.  CRISP Points on Establishing CRISPR-Cas9 In Vitro Culture Experiments in a Resource Constraint Haematology Oncology Research Lab.

Authors:  Jhumki Das; Prateek Bhatia; Aditya Singh
Journal:  Indian J Hematol Blood Transfus       Date:  2018-09-17       Impact factor: 0.900

3.  CRISPR, animals, and FDA oversight: Building a path to success.

Authors:  Laura R Epstein; Stella S Lee; Mayumi F Miller; Heather A Lombardi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-30       Impact factor: 11.205

Review 4.  Delivery technologies for genome editing.

Authors:  Hao Yin; Kevin J Kauffman; Daniel G Anderson
Journal:  Nat Rev Drug Discov       Date:  2017-03-24       Impact factor: 84.694

5.  Genomic targeting of epigenetic probes using a chemically tailored Cas9 system.

Authors:  Glen P Liszczak; Zachary Z Brown; Samuel H Kim; Rob C Oslund; Yael David; Tom W Muir
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

Review 6.  Non-viral delivery of genome-editing nucleases for gene therapy.

Authors:  M Wang; Z A Glass; Q Xu
Journal:  Gene Ther       Date:  2016-10-31       Impact factor: 5.250

Review 7.  What rheumatologists need to know about CRISPR/Cas9.

Authors:  Gary J Gibson; Maozhou Yang
Journal:  Nat Rev Rheumatol       Date:  2017-02-09       Impact factor: 20.543

8.  Easy In Vitro Synthesis of Optimised Functioning Reporter mRNA from Common eGFP Plasmid.

Authors:  Gustavo Torres de Souza; Rafaela Chitarra Rodrigues Hell; Jéssica Fernanda da Silva Souza; Luiz Sérgio de Almeida Camargo
Journal:  Mol Biotechnol       Date:  2018-10       Impact factor: 2.695

9.  Highly efficient genome editing of human hematopoietic stem cells via a nano-silicon-blade delivery approach.

Authors:  Yuan Ma; Xin Han; Oscar Quintana Bustamante; Ricardo Bessa de Castro; Kai Zhang; Pengchao Zhang; Ying Li; Zongbin Liu; Xuewu Liu; Mauro Ferrari; Zhongbo Hu; José Carlos Segovia; Lidong Qin
Journal:  Integr Biol (Camb)       Date:  2017-06-19       Impact factor: 2.192

10.  Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles.

Authors:  Zeming Chen; Fuyao Liu; Yanke Chen; Jun Liu; Xiaoying Wang; Ann T Chen; Gang Deng; Hongyi Zhang; Jie Liu; Zhangyong Hong; Jiangbing Zhou
Journal:  Adv Funct Mater       Date:  2017-10-16       Impact factor: 18.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.